Skip to main content Skip to search Skip to main navigation
News: Europe

European Commission: Steps to Ensure the Availability of Medicines

On 24 October 2023, the European Commission adopted steps to prevent drug shortages and increase the security of supply in the European Union.

Following supply disruptions in the EU lately, the Commission, with the help of other authorities and associations, has developed a set of measures to prevent critical shortages of key medicines in the future.

In preparation, the European Health Emergency Preparedness and Response Authority (HERA) and the European Medicines Agency (EMA) have already identified the key antibiotics expected to face shortages during the winter months.

In addition, the following measures have been and are being taken:

  • a voluntary solidarity mechanism allows member states to share medicines among themselves
  • a Union list of critical medicines will be established to identify weak links in the supply chain
  • regulatory flexibilities to ensure rapid access to medicines
  • EU guidelines on drug procurement to increase security of supply
  • a joint procurement of antibiotics and respiratory therapeutics on EU level for the next winter

Regulatory flexibilities for essential medicines are expected to be a key element. This is specifically aimed to accelerate the approval and introduction of alternative medicines, to increase production and approval of alternative suppliers, to temporarily extend the shelf life of products, and to allow for the redistribution of medicines between member states.

The European Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) has provided further insight into how these flexibilities will be applied this winter. Competent authorities will decide on a case-by-case basis whether recommendations will be implemented.

To secure the long-term supply of medicines, the Commission plans to establish a Critical Medicines Alliance that will focus on particularly important medicines. This alliance will include measures to diversify manufacturing and modernize supply chains. It is expected to be launched early next year.

The availability of medicines worldwide requires international cooperation and partnerships, including with third countries.


Source:

EC: Press release

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next